Investigation of serum biomarker for prediction of efficacy of the treatments for inflammatory bowel disease

Investigation of serum biomarker for prediction of efficacy of the treatments for inflammatory bowel disease - Biomarker for IBD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014201

Enrollment

500

Registered

2014-06-06

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel diseases(ulcerative colitis, crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with inflammatory bowel diseases(ulcerative colitis, Crohn's disease), Behcet disease 2)Patients who will use or are using biologics (infliximab and adalimumab)

Exclusion criteria

Exclusion criteria: 1) Patients with mental diseases 2) Patients younger than 16 years old. 3) Patients who are not suitable to attend this study judged by physicians.

Design outcomes

Primary

Measure	Time frame
The titers of biomarkers(serum oligosaccharides in immunoglobulins and cytokines)	—

Countries

Japan

Contacts

Public ContactHideki Iijima

Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology

hiijima@gh.med.osaka-u.ac.jp+81-6-6879-3621

Outcome results